Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First-Of-Its-Kind Autism Software Could Help Diagnose, Treat Children Faster: FDA

Executive Summary

The US agency says a lack of specialists often lead to delays in diagnosing children and prevents them from getting much-needed help during a treatment time frame, which the new breakthrough device can help fix.

You may also be interested in...



Cognoa Seeks De Novo Clearance For AI-Powered Diagnostic App For Autism After Successful Study

FDA clearance of the ASD Diagnostic app could lead to early diagnosis, improving quality of life of children with ASD and their caregivers. 

Verily’s Study Watch Rejected By FDA As Parkinson’s Drug-Development Tool

US regulators say Verily’s Study Watch – meant to be used in Parkinson’s trials – doesn’t collect data needed to assess whether a patient is truly benefitting from a drug.

FDA Says SBOMs Are Key To Better Cybersecurity In NIST Report

The US regulator’s report is meant to help develop new federal cybersecurity purchasing guidelines that could eventually be used to implement a cybersecurity consumer labeling program.

Topics

UsernamePublicRestriction

Register

MT144014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel